Following the announcement on the 8th of August 2018 of the sale of Aquilant by UDG Healthcare plc to H2 Equity Partners and the subsequent agreement reached by H2 Equity Partners and the Healthcare 21 Group, we are excited to announce the creation of a new market-leading group consisting of Aquilant and Healthcare 21 (the envisaged transaction is subject only to Irish Competition Authority approval, which is expected by the end of September 2018).

 

The combined companies will have a turnover in excess of €150m and employ 450 people across Ireland, the UK, Germany and Austria. The businesses complement each other extremely well and the combined group offers an expanded product portfolio in many exciting therapy areas. In addition, the Aquilant business expertise and infrastructure will ensure that both companies can maintain focus on their current plans and continue to deliver world class outcomes for our customers and suppliers alike.

 

Aquilant, Healthcare 21 and H2 expect our growth to continue as we drive to become Europe’s largest and best in class provider of outsourced sales, marketing and service solutions for our suppliers and to our customers.

 

About Aquilant Ltd

Aquilant is a leading provider of specialist healthcare and scientific products and services, including outsourced sales, marketing, distribution and engineering for the medical and scientific sectors. Aquilant has well established businesses and infrastructure in the UK and Ireland providing innovative products and solutions to their markets for leading international manufacturers.

 

About Healthcare 21 Group

Healthcare 21 is one of Northern Europe’s largest privately owned healthcare companies with operations across the UK, Germany, Austria and Ireland. They are a leading provider of sales, marketing, customer service, engineering service and logistics for a variety of leading global Healthcare manufacturers.

 

About H2 Equity Partners

H2 Equity Partners is a leading independent investment firm founded in 1991, making investments in medium-sized companies with significant growth or improvement potential. The H2 team has built an exceptional track record of acquiring, strengthening and growing fundamentally attractive businesses. H2 invests in companies across all sectors, that have strong market positions and competitive advantages, which can benefit from the extensive international operating experience of the H2 team.

 

For more information about Aquilant, HC21 or H2 Equity Partners please visit:

www.aquilant.net

www.healthcare21.eu

www.h2ep.co.uk